Startups
Arriello is a leading consultancy and solutions provider of risk management and compliance services to the pharmaceutical industry. We’ve been making the development-to-market process faster, better, and smarter since 2008.
Our global services span the product life cycle from Clinical to post-submission Regulatory Affairs and Pharmacovigilance, Quality Assurance and Auditing, and innovative automation solutions.
Headquartered in Ireland, with operations across Europe, we consult, create, and provide solutions across the EU, North America, LATAM, CIS, MENA, Asia, and South Africa.
With our extensive global network, decades of combined experience and ISO:9001 certification, we are a trusted partner primarily to pharmaceutical and biotech companies.
Our valued clients rely on our ability to deliver, however complex their requirements, through our proven expertise, global coverage, and technology.
Arriello.
From development to market. Faster. Better. Smarter.
Our global services span the product life cycle from Clinical to post-submission Regulatory Affairs and Pharmacovigilance, Quality Assurance and Auditing, and innovative automation solutions.
Headquartered in Ireland, with operations across Europe, we consult, create, and provide solutions across the EU, North America, LATAM, CIS, MENA, Asia, and South Africa.
With our extensive global network, decades of combined experience and ISO:9001 certification, we are a trusted partner primarily to pharmaceutical and biotech companies.
Our valued clients rely on our ability to deliver, however complex their requirements, through our proven expertise, global coverage, and technology.
Arriello.
From development to market. Faster. Better. Smarter.
Overview
Location
Ireland, Dublin City, Dublin
Employees
51-200
Founded date
2008
Mentions in press and media 9
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 15, 2023 | Arriello appoints experienced Pharmacovigilance expert, Sam Tomlinson as VP of Global Drug Safety | Sam Tomlinson Everyone at Arriello is delighted to welcome Sam on board as VP of Global Drug Safety. Her extensive experience in PV will help us provide more comprehensive safety services across the entire product lifecycle. DUBLIN (PRWEB) ... |
| Nov 29, 2022 | Arriello appoints distinguished regulatory expert, Pete Embley, as Chief Regulatory Officer | Pete Embley Regulatory is a key function within in the pharma and biotech world, so it feels right to join a business that positions this as a pivotal part of the business. DUBLIN (PRWEB) November 29, 2022 Arriello, a leading provider of in... |
| Oct 24, 2022 | 90% of pharma & biotech companies are already registered in EMA’s new clinical trials information system (CTIS), Arriello survey finds | It is encouraging to find such an enthusiastic early response, which we hope will continue to bear out as companies use it more actively to process applications for new trials. LEIPZIG, Germany (PRWEB) October 24, 2022 Arriello, a leading g... |
| Jan 5, 2022 | Arriello Welcomes High-Profile Pharmacovigilance leader Kieran O’Donnell as VP of Global Drug Safety | We are incredibly excited to welcome Kieran to our senior team, and to have the opportunity to work with a PV professional at his level. Kieran brings a breadth and degree of expertise that will see him take our already great systems and op... |
| Nov 4, 2021 | Arriello welcomes Helen Lowe, a leader in GVP Audit and Quality Assurance (QA), to its senior team | Arriello Auditing & QA Director Arriello is a service provider with big ambitions, which still retains a culture of being very personable and approachable for clients that need its support. The company has an impressive knowledge base, ... |
| Oct 14, 2021 | Arriello Board Advisors Publish Timely Market Strategy Advice as Biotechs Review their International PV Obligations | Judi, Eric, John and Panos bring exceptional and extensive global experience to help shape and direct our future pharmacovigilance strategy and operations. DUBLIN (PRWEB) October 14, 2021 Arriello, global experts in pharmacovigilance consul... |
| Oct 6, 2021 | Quality deemed more critical than price as companies progress with PV case intake automation, 2021 Arriello UK/US survey finds | PV automation makes quality assurance easy. It’s just a matter of overcoming validation requirements and providing ease of access. Usability issues and fear of the unknown are what hold people back, which is a shame given that integrating f... |
| Jan 26, 2021 | Arriello Announces Signing of First US Company to Use IntelliCASE for Clinical Pharmacovigilance Reporting | The app is completely intuitive and convenient to use, removing any practical or logistical barriers to Adverse Event reporting. DUBLIN (PRWEB) January 26, 2021 Arriello, a global expert in pharmacovigilance consulting and life science outs... |
Reviews 0
FAQ about Arriello
When was Arriello founded?
Arriello was founded in 2008.
What has the press written about Arriello?
Parsers VC has collected 9 articles mentioning Arriello, among them “Arriello appoints experienced Pharmacovigilance expert, Sam Tomlinson as VP of Global Drug Safety” (Mar 15, 2023) and “Arriello appoints distinguished regulatory expert, Pete Embley, as Chief Regulatory Officer” (Nov 29, 2022).
Is Arriello still active?
Yes, Arriello is active; its latest activity on Parsers VC dates from Oct 8, 2024.